Promega announced recently that its custom manufacturing is being recognized for supporting the rapid development of a Utah-based company’s new coronavirus test that received CE mark approval earlier this week. According…
Stemina Biomarker Discovery’s recent study on cardiovascular toxicity was published in the Toxicological Sciences journal this month, the company announced recently. According to a release, the study suggests that the results…
Nimble Therapeutics announced recently that it will enter a multi-year collaboration with Genentech to accelerate the discovery and development of novel peptide-based medicines. According to a release, the collaboration will leverage…
JangoBio announced today that it has created organoids that emulate the production of ovarian and testicular hormones. According to a release, JangoBio’s innovation has the capacity to regenerate and replace hormone-producing…
NorthStar Medical Radioisotopes received approval from the U.S. Food and Drug Administration (FDA) the addition of two molybdenum-99 (Mo-99) filling lines at its facility in Columbia, Mo., the company announced…
Dianomi Therapeutics has licensed a second suite of intellectual property (IP) from the Wisconsin Alumni Research Foundation (WARF) to expand the use of its Mineral Coated Microparticle (MCM) technology into…
NorthStar Medical Radioisotopes and Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, have signed a letter of intent for the commercial supply of copper-67 as an…
Phoenix has been awarded a $10 million indefinite quantity, indefinite delivery (IDIQ) contract with the U.S. Army, the company announced today. According to a release, the contract will demonstrate improved…
SHINE Medical Technologies, the Institute of Organic Chemistry and Biochemistry (IOCB Prague) and GE Healthcare announced today the production of patient-dose quantities of the therapeutic isotope lutetium-177 (Lu-177). According to…
SHINE Medical Technologies recently announced its 2019 year-end report, which included updates on its construction progress, continued investor support, its new therapeutics division and information about commercial and regulatory news….
